Cargando…
Development of Pelubiprofen Tromethamine with Improved Gastrointestinal Safety and Absorption
Pelubiprofen (PEL), which is a commercialized non-steroidal anti-inflammatory drug (NSAID), is associated with the risk of gastrointestinal (GI) adverse events following long-term exposure and has poor water-soluble properties. Here, a new pelubiprofen tromethamine (PEL-T) with improved solubility,...
Autores principales: | Park, Ji Yeon, Oh, Dong Ho, Park, Sang-Wook, Chae, Bo Ram, Kim, Chul Woo, Han, Sang Heon, Shin, Hyeon Jong, Yeom, Soo Bin, Lee, Da Yeong, Park, Min Kyu, Park, Sang-Eun, Park, Jun-Bom, Lee, Kyung-Tae |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158122/ https://www.ncbi.nlm.nih.gov/pubmed/34070062 http://dx.doi.org/10.3390/pharmaceutics13050745 |
Ejemplares similares
-
Pharmacokinetic and Pharmacodynamic Characteristics of Pelubiprofen Tromethamine vs. Pelubiprofen in Healthy Subjects
por: Son, Yu-Jeong, et al.
Publicado: (2023) -
Eccrine Squamous Syringometaplasia Associated with Pelubiprofen Therapy
por: Huh, Joon Won, et al.
Publicado: (2017) -
Comparison of the efficacy and safety profiles of a pelubiprofen versus celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, phase III, non-inferiority clinical trial
por: Choi, In Ah, et al.
Publicado: (2014) -
Sustained-release solid dispersion of pelubiprofen using the blended mixture of aminoclay and pH independent polymers: preparation and in vitro/in vivo characterization
por: Lee, Yeo-Song, et al.
Publicado: (2017) -
A Case of Vanishing Bile Duct Syndrome after Drug-Induced Liver Injury Caused by Pelubiprofen
por: Bak, Haein, et al.
Publicado: (2020)